Results of a randomized phase III study to compare the overall survival of gefitinib (IRESSA) versus docetaxel in Japanese patients with non-small cell lung cancer who failed one or two chemotherapy regimens

Seiji Niho,Yukito Ichinose,T. Tamura,N. Yamamoto,Masahiro Tsuboi,K. Nakagawa,T Shinkai,Haiyi Jiang,Yutaka Nishiwaki,Masahiro Fukuoka

Results of a randomized phase III study to compare the overall survival of gefitinib (IRESSA) versus docetaxel in Japanese patients with non-small cell lung cancer who failed one or two chemotherapy regimens

2007

Seiji Niho
Yukito Ichinose
T. Tamura
N. Yamamoto
Masahiro Tsuboi
K. Nakagawa
T Shinkai
Haiyi Jiang
Yutaka Nishiwaki
Masahiro Fukuoka

LBA7509 Background: This phase III study (V-15–32) compared gefitinib vs docetaxel on overall survival (OS) in Japanese patients (pts) with pretreated advanced NSCLC. Methods: Pts with advanced or ...

Keywords:

Chemotherapy
Lung cancer
Internal medicine
Oncology
Gefitinib
Cancer research
Medicine
Docetaxel
overall survival
non small cell

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations